VERAXA Biotech Highlights BiTAC Pipeline Progress, Advances Partnering Strategy

VERAXA Biotech (NASDAQ: VRXA) provided a corporate and pipeline update on July 6, 2026, highlighting progress during the first half of 2026, including continued advancement of its proprietary BiTAC platform and growing interest from potential pharmaceutical partners. The company said its pipeline now includes four BiTAC-based T-cell engager programs targeting solid tumors, two bispecific antibody-drug conjugate (ADC) programs and two non-BiTAC assets available for partnering.

VERAXA said it plans to prioritize investment in its BiTAC portfolio while seeking to monetize selected non-BiTAC programs to help finance future development, with the goal of advancing lead BiTAC-TCE candidate VXA-102 to IND/CTA readiness by early 2028. Company executives also cited strong industry interest in T-cell engager and ADC technologies, noting that recent partnering discussions at the BIO International Convention and other scientific meetings reinforced confidence in the company’s differentiated BiTAC platform and its potential to secure strategic collaborations.

VERAXA said it continues to refine both its pipeline and partnering strategy as it advances its next generation of cancer therapies. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. BiTAC is a registered trademark of VERAXA Biotech GmbH.

For more information, view the full press release at https://ibn.fm/xTF5q and the latest news and updates relating to VRXA in the company’s newsroom at https://ibn.fm/VRXA.

Forward-looking statements in this article involve risks and uncertainties that may cause actual results to differ materially. These include factors set forth under "Risk Factors" in the company's most recent Annual Report on Form 10-K and other SEC filings. Undue reliance should not be placed on these forward-looking statements.